H
Hubei Jumpcan Pharmaceutical Co Ltd
SSE:600566
Hubei Jumpcan Pharmaceutical Co Ltd
SSE:600566
Price:
27.76
CNY
3.24%
Market Cap:
¥25.6B
Relative Value
The Relative Value of one Hubei Jumpcan Pharmaceutical Co Ltd stock under the Base Case scenario is 17.94 CNY. Compared to the current market price of 27.76 CNY, Hubei Jumpcan Pharmaceutical Co Ltd is Overvalued by 35%.
Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.
Relative Valuation FAQ:
Relative Value
Base Case
17.94
CNY
Overvaluation 35%
H
Multiples Across Competitors
Competitors Multiples
Hubei Jumpcan Pharmaceutical Co Ltd Competitors
Hubei Jumpcan Pharmaceutical Co Ltd Competitors
All Countries
| Market Cap | P/S | P/E | EV/EBITDA | EV/EBIT | ||||
|---|---|---|---|---|---|---|---|---|
| CN |
H
|
Hubei Jumpcan Pharmaceutical Co Ltd
SSE:600566
|
25.6B CNY | 4.2 | 15.5 | 9.1 | 9.1 | |
| US |
|
Eli Lilly and Co
NYSE:LLY
|
867.4B USD | 13.3 | 42 | 28.4 | 30.3 | |
| US |
|
Johnson & Johnson
NYSE:JNJ
|
571.4B USD | 6.1 | 21.3 | 14.8 | 18.2 | |
| CH |
|
Roche Holding AG
SIX:ROG
|
257.8B CHF | 4.2 | 20 | 11.8 | 13.3 | |
| UK |
|
AstraZeneca PLC
LSE:AZN
|
220.3B GBP | 5 | 28.9 | 16 | 22.6 | |
| CH |
|
Novartis AG
SIX:NOVN
|
228.9B CHF | 5.2 | 21.1 | 13.1 | 16.8 | |
| US |
|
Merck & Co Inc
NYSE:MRK
|
283.3B USD | 4.4 | 15.5 | 9.6 | 11.7 | |
| IE |
E
|
Endo International PLC
LSE:0Y5F
|
240.1B USD | 103.6 | -82.1 | 380.1 | 953.2 | |
| DK |
|
Novo Nordisk A/S
CSE:NOVO B
|
1.1T DKK | 3.5 | 10.5 | 7.8 | 9.1 | |
| US |
|
Pfizer Inc
NYSE:PFE
|
155.3B USD | 2.5 | 20 | 7.7 | 10.2 | |
| US |
|
Bristol-Myers Squibb Co
NYSE:BMY
|
119.5B USD | 2.5 | 17 | 7.1 | 8.8 |
P/S Multiple
P/E Multiple
EV/EBITDA Multiple
EV/EBIT Multiple
